CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lallas, T. A.
Right arrow Articles by Buller, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lallas, T. A.
Right arrow Articles by Buller, R. E.
Cancer Epidemiology Biomarkers & Prevention Vol. 9, 587-590, June 2000
© 2000 American Association for Cancer Research

The Glutathione S-Transferase M1 Genotype in Ovarian Cancer

Thomas A. Lallas, Sarah K. McClain, Mark S. Shahin and Richard E. Buller1

Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Glutathione S-transferase mu-1 (GSTM1) is a polymorphic member of the mu class gene family of the glutathione S-transferases. Individuals who are GSTM1 null have increased susceptibility to lung and colon cancer. We hypothesized that: (a) GSTM1 null individuals might also be at increased risk for development of ovarian cancer; and (b) the GSTM1 genotype would influence response to chemotherapy. One hundred and forty-six individuals with invasive epithelial ovarian cancer were genotyped using a three-primer PCR reaction specific for the GSTM1 gene and an internal control glutathione S-transferase mu-4 (GSTM4). The products were analyzed on agarose gels. Healthy individuals without a family history of ovarian, breast, or colon cancer served as unmatched controls (n = 80). The results show that age at diagnosis, histological type, and stage of ovarian cancer were all independent of GSTM1 genotype. The frequency of the GSTM1 null genotype in the ovarian cancer cohort was similar to that in the control population, 51% versus 58%, P > 0.05. Likewise, median survival for individuals with advanced stage ovarian cancer was independent of GSTM1 genotype. We concluded that the GSTM1 null genotype does not increase ovarian cancer risk. These findings suggest that GSTM1 does not play a significant role in detoxifying environmental factors that influence ovarian carcinogenesis and does not play an important role in the resistance of ovarian cancer to chemotherapy.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
GSTM12 is a member of the mu class gene family of the GSTs. GSTs form a supergene family that can be subdivided into four distinct classes: alpha, mu, pi, and theta (1) . GSTs are soluble homodimeric enzymes that aid in detoxifying numerous compounds, including electrophilic carcinogens (2) . The mechanism involves the sulfur atom of glutathione acting as a nucleophilic substrate (3) . The resulting glutathione conjugate is then either directly excreted or further metabolized to a mercapturic acid (3 , 4) . Mercapturic acids are excreted in the urine and are the normal products of glutathione conjugates (3, 4, 5, 6) . This pathway of detoxifying xenobiotics can be extended to the role that glutathione-dependent enzymes play in chemotherapeutic drug resistance (3) . Depletion of cellular glutathione levels sensitizes cells to the toxic effects of a wide range of cytotoxic drugs, and augmentation of cellular glutathione enhances resistance against the toxic effects of these compounds. Black and Wolf (3) offer the above evidence to support the role of glutathione dependent enzymes in drug resistance.

Previous studies have shown GSTM1 is polymorphic in humans but expressed by only 12–69% of individuals (7, 8, 9, 10, 11) . GSTM1 has been primarily studied in lung, bladder, breast, and colon cancers (8, 9, 10 , 12) . The GSTM1 null genotype is defined as the absence of GSTM1 enzyme activity because of the deletion of both copies of the GSTM1 gene. Individuals who are GSTM1 null have been found to carry an increased susceptibility to lung and colon cancer (10 , 12) . Although definite associations with exposure to carcinogens have not been established, some epidemiological studies suggest ovarian cancer is associated with the use of talcum powder (13, 14, 15, 16, 17) . However, current biological and epidemiological data do not provide strong evidence for a causal association, because the dose-response trends are lacking (18) . Other factors, including body mass index, have been shown to confound the above relationship (19) . We hypothesized that GSTM1 null individuals might have an increased risk of developing ovarian cancer. Furthermore, the absence of the GSTM1 detoxification pathway was hypothesized as a mechanism that could make some ovarian cancers more sensitive to chemotherapy. We tested these hypotheses by comparing the frequency of GSTM1 null phenotypes among cohorts of ovarian cancer probands and unaffected individuals in a paid control population. In addition, we evaluated ovarian cancer survival as a function of GSTM1 genotype.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
The University of Iowa Division of Gynecological Oncology maintains a germ-line DNA bank for a variety of genetic studies related to ovarian cancer. Samples were obtained after informed consent approved by the Hospital Committee for the Protection of Human Subjects. One hundred and forty-six patients with invasive epithelial ovarian cancer were genotyped, along with 80 unmatched controls who had no family history of ovarian, breast, or colon cancer. A representative sample of 33 tumors from GSTM1-positive individuals was also genotyped to define whether a GSTM1 null tumor had developed in an individual who might have lost one or both copies of the GSTM1 gene. All patients were treated by The Division of Gynecological Oncology at The University of Iowa Hospitals and Clinics and were diagnosed with invasive epithelial ovarian cancer before January 1, 1996. Primary cytoreductive surgery included exploration of upper abdomen and pelvis; total abdominal hysterectomy and bilateral salpingo-oophorectomy; cytology from peritoneal washings or ascites; omentectomy; multiple peritoneal biopsies; and selective pelvic and para-aortic lymphadenectomy. The postoperative chemotherapy regimen included a platinum compound in combination with cyclophosphamide or paclitaxel.

DNA was extracted from whole blood cells and tumor tissue using conventional techniques of phenol/chloroform/isoamyl alcohol extraction and isopropanol precipitation. All DNA precipitates were resuspended in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0; Refs. 20 and 21 ). PCR amplification of the GSTM1 and GSTM4 loci was carried out using the method of Zhong et al. (12) . The PCR reaction used three primers: P1, 5'-CGCCATCTTGTCCTACATTGCCCG-3'; P2, 5'- ATCTTCTCCTCTTCTGTCTC-3'; and P3, 5'-TTCTGGATTGTAGCAGATCA-3'.

P1 and P3 amplify a 230-bp product that is specific for the GSTM1 gene. P3 anneals specifically to sequences in the GSTM1 gene. P1 and P2 can anneal to either the GSTM1 or GSTM4 gene and yield a 157-bp product. PCR was carried out in a total volume of 10.0 µl containing 20 ng of genomic DNA, 1.0 µl of 10x PCR buffer (15 mM MgCl2 at pH 9.0), 2.0 mM of each deoxynucleotide triphosphate, 1.0 µl of DMSO, 600 ng of P1, 300 ng each of P2 and P3, 3.12 µl of double-distilled H2O, and 0.2 µl of Taq polymerase (5 units/µl). The reaction was overlaid with 40 µl of white light mineral oil. The reaction was then heated to 94°C for 45 s for denaturation, cooled at 52°C for 45 s to allow annealing, followed by extension at 72°C for 45 s. This cycle was repeated 34 times. A terminal 5-min extension at 72°C completed the amplification. The products were then analyzed by electrophoresis on 2% agarose gel and detected by staining with ethidium bromide. If the product only displayed the GSTM4 (control) gene, it was classified as GSTM1 null, whereas if the GSTM1 gene and control were both present on the gel, it was classified as GSTM1 positive (Fig. 1)Citation . GSTM4 is another member of the GST mu class gene family but does not demonstrate a polymorphism.



View larger version (56K):
[in this window]
[in a new window]
  		Fig. 1. GSTM1 and GSTM4 gene PCR products resolved by agarose gel electrophoresis. A 157-bp DNA fragment representing the GSTM4 gene (control) is seen in Lanes 1–3 and 5. A 230-bp DNA fragment representing the GSTM1 gene is seen only in Lane 5. Lane 4, 1000-bp ladder.

 
Family History, Pedigree, Pathological Confirmation of Cancers, and Follow-Up.
A complete pedigree was obtained on each individual studied with pathological follow-up of reported breast, ovary, and colon cancer among family members when possible. Family history of breast, ovary, and colon cancer was determined by reviewing the proband’s pedigree to determine the number of relatives affected by these cancers. For this analysis, we counted only first-, second-, and third-degree relatives. A positive family history was noted if any ovarian, breast, or colon cancers were documented by pathological review or by death certificate.

Statistical Analysis.
The sample size to be evaluated was determined by a power analysis. Seidergard et al. (9) reported the prevalence rate of the GSTM1 null genotype to be 42% in controls. There was a 63% prevalence rate in the lung cancer population they studied (9) . Anticipating that we might find a similar difference, we calculated that there was an 80% chance of finding this difference with an {alpha} = 0.05 if we studied at least 186 individuals. Therefore, we studied 146 ovarian cancer cases and 80 controls.

Statistical calculations were completed using the Kruskal-Wallis test and the two-tailed, {chi}2 method. Survival curves were generated with the BMDP statistical software package (BMDP, Los Angeles, CA; 1990) using a Cox proportional hazards model. P < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
One hundred and thirty-eight of the 146 germ-line mononuclear DNA samples from individuals with invasive epithelial ovarian cancer were informative (Table 1)Citation . Seventy (51%) of informative samples were GSTM1 null. Eighty healthy females without a family history of ovarian, breast, or colon cancer were analyzed as controls. Seventy-seven were informative, and forty-five of these (58%) were GSTM1 null. This difference was not significant (P > 0.05).


View this table:
[in this window]
[in a new window]
  		Table 1 Comparison of ovarian cancer probands and unaffected healthy control females

 
Loss of a viable GSTM1 coding sequence in ovarian tumors could result in GSTM1 null tumors developing in individuals who were GSTM1 positive in the germ line. To evaluate this possibility, tumor DNA was genotyped from 33 GSTM-positive individuals. The same methods described above were used to analyze the tumor DNA. Thirty of the 33 tumors were also GSTM1 positive, whereas three tumors were GSTM1 null.

If detoxification mechanisms were dependent on GSTM1 to prevent carcinogenesis, a younger age of onset of disease would be predicted for GSTM1 null probands diagnosed with ovarian cancer. The median age of diagnosis was 56.3 years for the GSTM1 null individuals and 56.8 years for the GSTM1-positive individuals. This difference was not statistically significant. Histological subtypes of ovarian carcinoma and stage at diagnosis were also studied to ascertain whether GSTM1 null individuals develop a more aggressive cancer. These results are summarized in Table 2Citation . There was no statistically significant correlation between ovarian cancer histology (P > 0.05) or stage at diagnosis (P > 0.05) and the proband’s GSTM1 genotype.


View this table:
[in this window]
[in a new window]
  		Table 2 Comparison of ovarian cancer histology and stage at diagnosis to GSTM1 genotype

 
If GSTM1 plays a role in detoxifying chemotherapeutics as the pi class gene family of GSTs (GSTP) appear to do (22, 23, 24, 25, 26, 27, 28) , one would predict that GSTM1 null individuals would show a better initial response to chemotherapy than GSTM1-positive individuals. To test this hypothesis, survival rates in the ovarian cancer cohort with stage III or IV disease were generated based on GSTM1 genotype. These results are shown as Fig. 2Citation . This figure shows that survival is independent of GSTM1 genotype.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 2. Kaplan-Meier estimate of survival in individuals diagnosed with advanced stage ovarian cancer stratified on the basis of GSTM1 genotype.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Individuals are exposed to a whole host of environmental carcinogens throughout their lives. It is clear that some individuals with genetically compromised detoxification pathways are at increased risk for a variety of cancers. Epidemiological studies have implicated a role for environmental carcinogens in lung, bladder, breast, colon, and ovarian cancer (8 , 15, 16, 17 , 29, 30, 31, 32, 33, 34) . Smokers, for example, are at an increased risk for the development of lung, bladder, breast, and colon cancer (29, 30, 31, 32, 33) . Often, individuals with the same occupational and environmental exposures demonstrate different susceptibilities to cancer and may further demonstrate varying responses to the same treatments. These observations are consistent with an important role for genetics in modifying both cancer risk and treatment response.

The glutathione transferases are a family of enzymes that play a key role in detoxifying carcinogens (2) . Glutathione transferases were first studied by Seidegard et al. (8) , who proposed that expression of phase II detoxification enzymes including the glutathione transferases might help prevent lung cancer. In a series of studies, these investigators reported that smokers who failed to develop lung cancer were more likely to be GSTM1 positive. Conversely, GSTM1 null smokers were more likely to develop lung cancer, presumably secondary to compromised detoxification of tobacco-related carcinogens (8, 9 , 35) . Independently, Zhong et al. (10 , 12) reported a higher prevalence of the GSTM1 null genotype in colorectal carcinoma patients relative to a healthy control population. These investigators were unable to confirm Seidegard’s observations in a different lung cancer cohort and further found no increase in risk for bladder or breast cancer among GSTM1 null individuals. However, these analyses were significantly underpowered based on the small difference in prevalence of the GSTM1 null genotype between their cancer populations and their control population (10 , 12) .

In the present study, GSTM1 genotypes in an ovarian cancer cohort were compared with a control population selected to preclude a genetic risk for ovarian cancer. There was no difference in the prevalence of the GSTM1 null genotype in this ovarian cancer cohort (51%) compared with the control population (58%). Howells et al. (36) have just reported identical findings.

The observed frequency of the GSTM1 null genotype among ovarian cancer probands in the present study matches that reported by other investigators for ovarian as well as other cancers (9, 10 , 12 , 36) . The 58% prevalence of GSTM1 null individuals in our control population is similar to 61.5% in Howells et al. (36) control population. However, it is markedly higher than that reported by Seidegard or Zhong and was an unexpected finding (9, 10 , 12) .

The present study was powered at 80% to detect a difference between controls and ovarian cancer probands based on an expected 42% frequency of the GSTM1 null genotype in controls. The frequency of the GSTM1 null genotype in our ovarian cancer population was as expected. Unfortunately, the frequency of the GSTM1 null genotype in the control population was much higher than anticipated from the literature. Therefore, the power of the study was less then intended. To achieve the necessary power, a sample size of 1431 would have been required.

It is likely that some of the discrepancies among studies may be explained by differences in the ethnic makeup of the various study populations. London et al. (37) have reported that the GSTM1 null genotype is significantly higher in Caucasians than in African-Americans with lung cancer. Likewise, GSTM1 null rates have been reported to range between 31% and 88% when African-Americans and Samoans, respectively, are genotyped (11) . The population of ovarian cancer patients treated at The University of Iowa Hospitals and Clinics is almost exclusively of European extraction. This could account for the higher percentage of GSTM1 null individuals in the control population and emphasizes the importance of similar ethnic makeup of study and control populations for studies such as these. A similar phenomenon was observed with regard to the expression of the codon 72 polymorphism of the p53 gene (38) .

Others have also postulated that alpha and mu expression might correlate with the response of ovarian cancer to treatment (39) . We observed no difference in survival of individuals with advanced stage ovarian cancer genotyped as GSTM1 null compared with those who were GSTM1 positive. This is also consistent with the observations made by Howells et al. (36) , who found no association between the GSTM1 null genotype and survival. Howells et al. (36) did report poorer outcomes in women who were both GSTM1 null and GSTT1 null. However, only 12 of the 134 individuals studied were null at both loci (36) . Thus, the combination of these genetic markers is not overly helpful in predicting treatment outcomes among the vast majority of ovarian cancer patients.

The present results are contrary to those predicted by published studies of GSTP expression. GSTP expression has been uniformly related to chemotherapy resistance (22, 23, 24, 25, 26, 27, 28) . However, in both platinum-sensitive and -resistant ovarian cancer cell lines, there is complete absence of GSTM1 mRNA, consistent with clinical independence of platinum resistance from GSTM1. A possible explanation for this discrepancy might be subtle differences in GSTM1 and GSTP function, whereby in the complete absence of GSTM1, relatively more glutathione is available for GSTP, which may be more effective than GSTM1 in shunting chemotherapeutics away from their cytotoxic effects.

Given the failure to demonstrate a relationship between the GSTM1 genotype and the onset, extent, or aggressiveness of ovarian cancer, we can conclude that GSTM1 does not play a significant role in detoxifying environmental factors that influence ovarian carcinogenesis. In addition, the absence of an impact upon survival means that the GSTM1 genotype, contrary to the other GST genotypes, does not modify the overall relative resistance of many epithelial ovarian cancers to chemotherapy.


   Acknowledgments
 
We thank Alex Parker, Department of Preventive Medicine and Environmental Health–The University of Iowa Hospitals and Clinics, for assistance with the statistical analysis. We also thank Cathie Augustine and Marisa Dolan for technical assistance in DNA isolation.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242. Phone: (319) 356-2015; Fax: (319) 353-8363; E-mail: richard-buller{at}uiowa.edu Back

2 The abbreviations used are: GSTM1, glutathione S-transferase mu 1; GSTP, GST pi. Back

Received 9/ 3/99; revised 2/28/00; accepted 3/13/00.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Mannervik B., Awasthi Y. C., Board P. G., Hayes J. D., Di Ilio C., Ketterer B., Listowsky I., Morgenstern R., Muramatsu M., Pearson W. R., et al Nomenclature for human glutathione transferases. Biochem. J., 282: 305-308, 1992.
  2. Chasseaud L. F. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res., 29: 177-199, 1979.
  3. Black S. M., Wolf C. R. The role of glutathione-dependent enzymes in drug resistance. Pharmacol. Ther., 51: 139-154, 1991.[Medline]
  4. Jakoby W. B. . Metabolic Basis of Detoxification, I: II: Academic Press New York 1982.
  5. Mannervik B., Alin P., Guthenberg C., Jensson H., Tahir M. K., Warholm M., Jornvall H. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc. Natl. Acad. Sci. USA, 82: 7202-7206, 1985.[Abstract/Free Full Text]
  6. Mannervik B. The isoenzymes of glutathione transferase. Adv. Enzymes, 57: 357-415, 1985.
  7. Harada S., Abei M., Tanaka N., Agarwal D. P., Goedde H. W. Liver glutathione S-transferase polymorphism in Japanese and its pharmacogenetic importance. Hum. Genet., 75: 322-325, 1987.[Medline]
  8. Seidergard J., Pero R. W., Miller D. G., Beattie E. J. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis (Lond.), 7: 751-753, 1986.[Abstract/Free Full Text]
  9. Seidergard J., Pero R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis (Lond.), 11: 33-36, 1990.[Abstract/Free Full Text]
  10. Zhong S., Howie A. F., Ketterer B., Taylor J., Hayes J. D., Beckett G. J., Wathen C. G., Wolf C. R., Spurr N. K. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis (Lond.), 12: 1533-1537, 1991.[Abstract/Free Full Text]
  11. Lin H. J., Han C-Y., Bernstein D. A., Hsiao W., Lin B. K., Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis (Lond.), 15: 1077-1081, 1994.[Abstract/Free Full Text]
  12. Zhong S., Wyllie A. H., Barnes D., Wolf C. R., Spurr N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast, and colon cancer. Carcinogenesis (Lond.), 14: 1821-1824, 1993.[Abstract/Free Full Text]
  13. Wittemore A. S., Wu M. L., Paffenbarger R. S., Sarles D. L., Kampert J. B., Grosser S., Jung D. L., Ballon D. L., Hendricksen M. Personal and environmental characteristics related to epithelial ovarian cancer: II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am. J. Epidemiol., 128: 1228-1240, 1988.[Abstract/Free Full Text]
  14. Longo D. L., Young R. C. Cosmetic talc and ovarian cancer. Lancet, 2: 349 1979.[Medline]
  15. Harlow B. L., Cramer D. W., Bell D. A., Welch W. R. Perineal exposure to talc and ovarian cancer risk. Obstet. Gynecol., 80: 19-26, 1992.[Abstract/Free Full Text]
  16. Cook L. S., Kamb M. L., Weiss N. S. Perineal powder exposure and the risk of ovarian cancer. Am. J. Epidemiol., 145: 459-465, 1997.[Abstract/Free Full Text]
  17. Chang S., Risch H. A. Perineal talc exposure and risk of ovarian carcinoma. Cancer (Phila.), 79: 2396-401, 1997.[Medline]
  18. Muscat J. E., Wynder E. L. Re. "Perineal powder exposure and the risk of ovarian cancer.". Am. J. Epidemiol., 146: 786 1997.[Free Full Text]
  19. Rosenblatt K. A., Mathews W. A., Daling J. R., Voigt L. F., Malone K. Characteristics of women who use perineal powders. Obstet. Gynecol., 92: 753-756, 1998.[Abstract]
  20. Buller R. E., Anderson B., Conner J. P., Robinson R. Familial ovarian cancer. Gynecol. Oncol., 51: 160-166, 1993.[Medline]
  21. Skilling J. S., Powills K., Lager D. J., Anderson B., Sorosky J., Buller R. E. p53 Allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol. Oncol., 61: 180-188, 1996.[Medline]
  22. Bhalla K., Holladay C., Lutzky J., Ibrado A. M., Bullock G., Jasiok M., Singh S. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol., 45: 32-39, 1992.[Medline]
  23. Oguchi H., Kikkawa F., Kojima M., Maeda O., Mizuno K., Suganuma N., Kawai M., Tomoda Y. Glutathione related enzymes in cis-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian carcinoma cells. Anticancer Res., 14: 193-200, 1994.[Medline]
  24. van der Zee G. J., Hollema H., Suurmeijer A. J. H., Krans M., Sluiter W. J., Willemse P. H. B., Aalders J. G., de Vries E. G. E. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol., 13: 70-78, 1995.[Abstract/Free Full Text]
  25. Toffoli G., Viel A., Tumiotto L., Giannini F., Volpe R., Quaia M., Boiocchi M. Expression of glutathione-S-transferase-{pi} in human tumors. Eur. J. Cancer, 28: 1441-1446, 1992.
  26. Okuyama T., Maehara Y., Endo K., Baba H., Adachi Y., Kuwano M., Sugimachi K. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer (Phila.), 74: 1230-1236, 1994.[Medline]
  27. Morgan A. S., Ciaccio P. J., Tew K. D., Kauvar L. M. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in culture human tumor cell lines. Cancer Chemother. Pharmacol., 37: 363-370, 1996.[Medline]
  28. Ban N., Takahashi Y., Takayama T., Kura T., Katahira T., Sakamaki S., Niitsu Y. Transfection of glutathione S-transferase (GST)-{pi} antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 56: 3577-3582, 1996.[Abstract/Free Full Text]
  29. Ernster V. L. Female lung cancer. Annu. Rev. Public Health, 17: 97-114, 1996.[Medline]
  30. Ross R. K., Jones P. A., Yu M. C. Bladder cancer epidemiology and pathogenesis. Semin. Oncol., 23: 536-545, 1996.[Medline]
  31. Cohen S. M., Johansson S. L. Epidemiology and etiology of bladder cancer. Urol. Clin. North Am., 19: 421-428, 1992.[Medline]
  32. Li D., Wang M., Dhingra K., Hittelman W. N. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res., 56: 287-293, 1996.[Abstract/Free Full Text]
  33. Heineman E. F., Zahm S. H., McLaughlin J. K., Vaught J. B. Increased risk of colorectal cancer among smokers: results of a 26 year follow-up of U. S. veterans and a review. Int. J. Cancer, 59: 728-738, 1995.
  34. Ziegler R. G., Hoover R. N., Pike M. C., Hildesheim A., Nomura A. M. Y., West D. W., Wu-Williams A. H., Kolonel L. N., Horn-Ross P. L., Rosenthal J. F., Hyer M. B. Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst., 85: 1819-1827, 1993.[Abstract/Free Full Text]
  35. Seidegard J., Vorachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathione transferase activity on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA, 85: 7293-7297, 1988.[Abstract/Free Full Text]
  36. Howells R. E. J., Redman C. W. E., Dhar K. K., Sarhanis P., Musgrove C., Jones P. W., Alldersea J., Fryer A. A., Hoban P. R., Strange R. C. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin. Cancer Res., 4: 2439-2445, 1998.[Abstract/Free Full Text]
  37. London S. J., Daly A. K., Cooper J., Navidi W. C., Carpenter C. L., Idle J. R. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J. Natl. Cancer Inst., 87: 1246-1253, 1995.[Abstract/Free Full Text]
  38. Buller R. E., Sood A., Fullencamp C., Sorosky J., Powills K., Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther., 4: 239-245, 1997.[Medline]
  39. Schisselbauer J. C., Hogan W. M., Buetow K. H., Tew K. D. Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. Pharmacogenetics, 2: 63-72, 1992.[Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. B. Ambrosone, C. Sweeney, B. F. Coles, P. A. Thompson, G. Y. McClure, S. Korourian, M. Y. Fares, A. Stone, F. F. Kadlubar, and L. F. Hutchins
Polymorphisms in Glutathione S-Transferases (GSTM1 and GSTT1) and Survival after Treatment for Breast Cancer
Cancer Res., October 1, 2001; 61(19): 7130 - 7135.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. B. Spurdle, P. M. Webb, D. M. Purdie, X. Chen, A. Green, and G. Chenevix-Trench
Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype
Carcinogenesis, January 1, 2001; 22(1): 67 - 72.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lallas, T. A.
Right arrow Articles by Buller, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lallas, T. A.
Right arrow Articles by Buller, R. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online